Literature DB >> 6821455

Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes.

M Rella, D Haas.   

Abstract

Resistance to high concentrations of nalidixic acid in Pseudomonas aeruginosa PAO was due to mutations in one locus designated nalA, which was mapped by transduction between hex-9001 and leu-10. The nalA mutants were cross-resistant to pipemidic acid, a nalidixic acid analog, at relatively low concentrations. Replicative DNA synthesis was resistant to both drugs in permeabilized cells of nalA mutants. A locus coding for low-level resistance to nalidixic acid, nalB, was cotransducible with pyrB, proC, and met-28. The nalB mutants were also resistant to low levels of pipemidic acid, novobiocin, and beta-lactam antibiotics (e.g., carbenicillin, azlocillin, and cefsulodin), but not to other drugs, such as gentamicin, rifampin, kanamycin, or tetracycline. In nalB mutants, DNA replication showed wild-type sensitivity to nalidixic acid, whereas carbenicillin-induced filamentation required higher drug levels than in the wild-type strain. Thus, nalB mutations appear to decrease cell permeability to some antibiotics. The sensitivity of replicative DNA synthesis to nalidixic acid and novobiocin was very similar in P. aeruginosa and Escherichia coli; by contrast, the concentrations of these drugs needed to inhibit growth of P. aeruginosa were higher than those reported for E. coli by one or two orders of magnitude.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6821455      PMCID: PMC183719          DOI: 10.1128/AAC.22.2.242

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

Review 1.  Chromosomal genetics of Pseudomonas.

Authors:  B W Holloway; V Krishnapillai; A F Morgan
Journal:  Microbiol Rev       Date:  1979-03

2.  DNA gyrase and DNA supercoiling.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; H Ohmori; J Tomizawa
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1979

3.  DNA gyrase: purification and catalytic properties of a fragment of gyrase B protein.

Authors:  M Gellert; L M Fisher; M H O'Dea
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

Review 4.  The outer membrane of Gram-negative bacteria.

Authors:  H Nikaido; T Nakae
Journal:  Adv Microb Physiol       Date:  1979       Impact factor: 3.517

5.  Chromosome mapping in Pseudomonas aeruginosa PAT.

Authors:  J M Watson; B W Holloway
Journal:  J Bacteriol       Date:  1978-03       Impact factor: 3.490

6.  Linkage map of Pseudomonas aeruginosa PAT.

Authors:  J M Watson; B W Holloway
Journal:  J Bacteriol       Date:  1978-11       Impact factor: 3.490

7.  Susceptibility of lipopolysaccharide-defective mutants of Pseudomonas aeruginosa strain PAO to dyes, detergents, and antibiotics.

Authors:  A M Kropinski; L Chan; F H Milazzo
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

8.  Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids.

Authors:  S Inoue; T Ohue; J Yamagishi; S Nakamura; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

9.  Chromosome mobilization by the R plasmid R68.45: a tool in Pseudomonas genetics.

Authors:  D Haas; B W Holloway
Journal:  Mol Gen Genet       Date:  1978-01-17

10.  MECHANISM OF ACTION OF NALIDIXIC ACID ON ESCHERICHIA COLI.II. INHIBITION OF DEOXYRIBONUCLEIC ACID SYNTHESIS.

Authors:  W A GOSS; W H DEITZ; T M COOK
Journal:  J Bacteriol       Date:  1965-04       Impact factor: 3.490

View more
  75 in total

1.  Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa.

Authors:  T Köhler; S F Epp; L K Curty; J C Pechère
Journal:  J Bacteriol       Date:  1999-10       Impact factor: 3.490

2.  Resistance to beta-lactam antibiotics in Pseudomonas aeruginosa due to interplay between the MexAB-OprM efflux pump and beta-lactamase.

Authors:  T Nakae; A Nakajima; T Ono; K Saito; H Yoneyama
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 3.  Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 4.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

5.  Mutations affecting DNA-binding activity of the MexR repressor of mexR-mexA-mexB-oprM operon expression.

Authors:  Kohjiro Saito; Hiroyuki Akama; Eisaku Yoshihara; Taiji Nakae
Journal:  J Bacteriol       Date:  2003-10       Impact factor: 3.490

Review 6.  Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance.

Authors:  Peter Gilbert; Andrew J McBain
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

7.  A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa.

Authors:  L J Piddock; M C Hall; F Bellido; M Bains; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

8.  Arginine degradation in Pseudomonas aeruginosa mutants blocked in two arginine catabolic pathways.

Authors:  D Haas; H Matsumoto; P Moretti; V Stalon; A Mercenier
Journal:  Mol Gen Genet       Date:  1984

9.  Contribution of permeability and sensitivity to inhibition of DNA synthesis in determining susceptibilities of Escherichia coli, Pseudomonas aeruginosa, and Alcaligenes faecalis to ciprofloxacin.

Authors:  J Bedard; S Chamberland; S Wong; T Schollaardt; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

10.  Factors influencing the accumulation of ciprofloxacin in Pseudomonas aeruginosa.

Authors:  R A Celesk; N J Robillard
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.